Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialSilvio Danese, Wit Danilkiewicz, Remo Panaccione et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 72
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trialsRemo Panaccione, Mary Ellen Frustaci, Kitty Y. Wan et al.|The Lancet|2025Cited by 44
EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIESRemo Panaccione, Bruce E. Sands, Silvio Danese et al.|Gastroenterology|2024Cited by 28
455 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON ENDOSCOPIC OUTCOME MEASURES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDYGeert D’Haens, Brian G. Feagan, David T. Rubin et al.|Gastroenterology|2021Cited by 9
Fr532 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDYBruce E. Sands, William J. Sandborn, Silvio Danese et al.|Gastroenterology|2021Cited by 5